- Home
- RVMD vs XPO Comparison
RVMD vs XPO Comparison
Compare RVMD & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | XPO |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 21.3B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | RVMD | XPO |
|---|---|---|
| Price | $148.84 | $210.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | $135.05 | ★ $175.82 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.64 |
| Revenue | N/A | ★ $7,744,000,000.00 |
| Revenue This Year | N/A | $5.50 |
| Revenue Next Year | $411.49 | $6.53 |
| P/E Ratio | ★ N/A | $80.52 |
| Revenue Growth | N/A | ★ 0.34 |
| 52 Week Low | $34.00 | $91.66 |
| 52 Week High | $148.00 | $220.50 |
Technical Indicators
Market Signals| Indicator | RVMD | XPO |
|---|---|---|
| Relative Strength Index (RSI) | 86.95 | 62.30 |
| Support Level | $93.39 | $123.93 |
| Resistance Level | N/A | $220.50 |
| Average True Range (ATR) | 4.31 | 6.89 |
| MACD | 6.08 | 1.64 |
| Stochastic Oscillator | 97.20 | 81.55 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.